Skip to content

Middle Meatal Bacteriology During Acute Respiratory Infection in Children

Clinical Relevance of Middle Meatal Bacteriology During Acute Respiratory Infection in Children - Randomised, Double-Blinded Clinical Study

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00545961
Enrollment
120
Registered
2007-10-18
Start date
2007-11-30
Completion date
2009-12-31
Last updated
2007-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Infection, Sinusitis

Keywords

respiratory infection, sinusitis, rhinosinusitis, children, middle meatal specimens, respiratory track bacteria, amoxicillin-clavulanate, pneumococci, haemophilus, moraxella

Brief summary

The purpose of this study is to find out whether the children with respiratory infection and the presence of pathogenic bacteria (S. pneumoniae, H. influenzae or M. catarrhalis) in the nasal middle meatus benefit from antimicrobial treatment.

Detailed description

Acute sinusitis is one of the most common disease in children requiring antimicrobial treatment. The diagnosis and treatment outcomes of acute sinusitis are contradictory, and better diagnostic criteria are needed. In adults with acute maxillary sinusitis, bacterial culture results obtained from the nasal middle meatus are comparable to those obtained from sinus puncture and aspiration. In children, the presence of pathogenic bacteria (S. pneumoniae, H. influenzae or M. catarrhalis) in the nasal middle meatus during respiratory infection predicts longer duration of signs and symptoms of common cold. In this randomized placebo-controlled study, the effect of the antimicrobial treatment (amoxicillin-clavulanate) is examined in children with pathogenic bacteria (S. pneumoniae, H. influenzae or M. catarrhalis) in the nasal middle meatus during respiratory infection. The duration of the symptoms and speed of recovery is recognized by daily symptom-diary, the results are compared between the treatment groups.

Interventions

DRUGamoxicillin clavulanate acid

mixture 0.28125 ml / kg twice a day for 7 days

DRUGplacebo

mixture, 0.28125 ml/kg twice a day for 7 days

Sponsors

Oulu University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
6 Years to 13 Years
Healthy volunteers
No

Inclusion criteria

* acute respiratory infection with nasal symptoms (nasal obstruction or discharge) * seeking medical help from health centre for the respiratory symptoms * pathogenic bacteria (S pneumoniae, H influenzae or M catarrhalis) identified from right or left nasal middle meatus in the endoscopically taken swab culture sampling taken by a study investigator (all microbiological analyses are done by the National Public Health Institute´s microbiological laboratory in Oulu)

Exclusion criteria

* otitis, tonsillitis or other disease requiring antimicrobial treatment * respiratory infection within 4 weeks of screening * antimicrobial treatment within 4 weeks of screening * allergy to penicillin or amoxicillin

Design outcomes

Primary

MeasureTime frame
Duration of continuous daily symptoms of the acute respiratory infection diagnosed at the study entry.within the first 3 weeks after enrolment

Secondary

MeasureTime frame
duration (days)and severity (grade mild, severe) of different symptoms (clear nasal discharge, coloured nasal discharge, nasal obstruction, cough, throat pain, ear ache, fever, headache, diarrhea)within the first three weeks after enrolment
number of days the child is using the following symptomatic drugs (pain killers, nasal vasoconstrictors, nasal corticosteroids, asthma drugs, antihistamines)within the first three weeks after the enrolment
number of days the child is not at school and that the parents are not at workwithin the first three weeks after enrolment

Countries

Finland

Contacts

Primary ContactAila A Kristo, MD
aila.kristo@ppshp.fi+35883153492
Backup ContactOlli-Pekka Alho, MD
olli-pekka.alho@oulu.fi+35883153473

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026